Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

NCT05185622 is registered in ClinicalTrials.gov with Santhera Pharmaceuticals as lead sponsor.

NCT NCT05185622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05185622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
Santhera Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 21, 2022
Completion date
July 16, 2024
Enrollment
54 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy